Rasmus O. Bak, Ph.D.

We like the modified synthetic sgRNAs because we can screen them directly in our cell type of interest. We don’t need to worry about translation between cell lines and primary cells at all because we are using the same guides and the same system that we are eventually going to use for therapy.